Browse Trials

➤

Find Breast Cancer Clinical Trials That Are Right For You

The clinical trials listed below are open in the U.S. for people with DCIS (stage 0), stage 1, stage 2, stage 3, or stage 4 (metastatic)
breast cancer. Clinical trials are available for people who are newly diagnosed with breast cancer, currently in treatment, experiencing
breast cancer recurrence, living with metastatic disease, as well as breast cancer survivors who have completed treatment.

Use the search box and filters to find a trial that’s right for you.

Currently viewing trials
(Last updated: January 10, 2025)

and or

Reset

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

All U.S.

Early stage

Advanced

Treatment

Non-treatment

Phase I II III

Display Only New Trials

AKT

ALK

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

dMMR/MSI-H

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

ROS1

TP53

NEAREST SITE: 8 miles
Epic Care Partners in Cancer Care
Emeryville,CA

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT03723928

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer (SWOG-S1703) Scientific Title

Purpose

To study if blood tests that look for tumor markers are as good as or better than imaging with PET and/or CT scans (the current standard of care) to determine if a tumor is growing.

Who is this for?

People with metastatic (stage IV) hormone positive (ER+ and/or PR+), HER2 negative (HER2-) breast cancer who are planning to have first line treatment for metastatic disease or have started treatment within the past month, and have at least one elevated tumor marker. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Standard of care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), at least every 3 months, ongoing</li> <li class="seamTextUnorderedListItem">Tumor Marker Test, if ordered by your doctor</li> </ul> Group 2: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Tumor Marker Tests, every 1 to 2 months, ongoing</li> <li class="seamTextUnorderedListItem">Imaging (CT and/or PET scans), only if need is shown by a Tumor Marker Test</li> </ul> Additional procedures <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Blood draws</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This imaging trial will compare using blood tests to PET/CT scans for monitoring tumor growth. </li> <li class="seamTextUnorderedListItem">The tumor markers that will be tested for in this study are CA 15-3, CA27.29, and CEA.</li> <li class="seamTextUnorderedListItem">The imaging tests will be those ordered by your doctor.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03723928' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/blood_marker' target='_blank'>Breastcancer.org: Blood Marker Tests</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/about-us/collaborations/top-five-list-oncology/choosing-wisely®-top-five-cancer-related-tests-procedures-and-treatments-many-patients-do-not-need/topic-4-follow-tumor-marker-tests-and-imaging-tests-people-treated-breast-cancer' target='_blank'>ASCO Cancer.net: Follow-up Tumor Marker Tests and Imaging Tests for People Treated for Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet' target='_blank'>NCI: Tumor Markers</a> </li><li class='seamTextUnorderedListItem'><a href='https://ozarkscancerresearch.org/wp-content/uploads/2019/04/SWOG-S1703.pdf' target='_blank'>Cancer Research for the Ozarks: Trial Information Page</a> </li></ul>

NEAREST SITE: 336 miles
Ethan Lam
Los Angeles,CA

VISITS: 2-3 visits

PHASE: I

NCT ID: NCT04147494

PET/CT Scans Before Surgery for People with Stage I-IV Breast Cancer

PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46 in Patients With Non-prostate Cancers: an Exploratory Study With Histopathology Validation Scientific Title

Purpose

To study where 68Ga-FAPi-46 and 68Ga-PSMA-11 accumulate in normal and cancer tissues and whether PET/CT scans with 68Ga-FAPi-46 and 68Ga-PSMA-11 can help locate cancer in the body.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are planning to receive surgery to remove the primary tumor and/or metastasis. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-FAPi-46, by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FDG, by IV, 1 time</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-PSMA-11, by IV, 1 time (optional)</li> <li class="seamTextUnorderedListItem">PET/CT scan, 1 time (optional)</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">68Ga-FAPi-46 and 68Ga-PSMA-11 are experimental tracers for imaging scans that may help locate cancer in the body.</li> <li class="seamTextUnorderedListItem">18F-FDG is a tracer routinely used for imaging scans that helps locate cancer in the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scanner combines the PET and the CT scanners into a single device. This device combines the anatomic (body structure) information provided by the CT scan with the metabolic (body processes) information obtained from the PET scan. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04147494' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/cancer-care/patient-education/pet-ct-fdg' target='_blank'>Memorial Sloan Kettering Cancer Center: PET/CT Scans with 18F-FDG Tracer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gallium-ga-68-fapi-46' target='_blank'>National Cancer Institute: 68Ga-FAPi-46</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/gallium-ga-68-psma-11-intravenous-route/description/drg-20506366' target='_blank'>Mayo Clinic: 68Ga-PSMA-11</a> </li></ul>

NEAREST SITE: 339 miles
Saint John's Cancer Institute
Santa Monica,CA

VISITS: 2 visits

PHASE: II

NCT ID: NCT05710328

DIRECT: PET/CT Scan to Predict Response to Chemotherapy Before Surgery for Stage II-III HER2 Positive Breast Cancer

Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial Scientific Title

Purpose

To use of PET/CT scans with FDG to help doctors decide if a person needs more or less neoadjuvant (before surgery) chemotherapy to get the best response.

Who is this for?

People with stage II or stage III newly diagnosed HER2 positive (HER2+) breast cancer who have not yet received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with FDG, by IV, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FDG is a radioactive tracer that is given in a vein before PET/CT scans to help identify areas of active cancer. </li> <li class="seamTextUnorderedListItem">PET and and CT scans are imaging techniques that make detailed, computerized pictures of areas inside the body.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05710328' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://ecog-acrin.org/clinical-trials/ea1211-direct-breast-cancer/' target='_blank'>ECOG-ACRIN Cancer Research Group: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/certain-pet-scan-detects-recurrence-better' target='_blank'>Breastcancer.org: FDG PET/CT Scan</a> </li></ul>

NEAREST SITE: 348 miles
Los Angeles County-USC Medical Center
Los Angeles,CA

VISITS: 1 visit

PHASE: I

NCT ID: NCT06171607

Contrast-Enhanced Ultrasound to Identify Breast Masses

Characterizing Breast Masses Using an Integrative Framework of Machine Learning and Radiomics Scientific Title

Purpose

To learn if using contrast-enhanced ultrasound (CEUS) will help to determine if an ultrasound-guided biopsy is necessary.

Who is this for?

Women who are planning to receive an ultrasound-guided biopsy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced ultrasound (CEUS) scan with Lumason or DEFINITY contrast agent, by IV, 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasounds use sound waves to produce images of structures within your body without using radiation. Ultrasounds are widely used to diagnose many diseases in the body.</li> <li class="seamTextUnorderedListItem">A contrast-enhanced ultrasound (CEUS) is an ultrasound given with a contrast agent that helps improve images obtained from the scan.</li> <li class="seamTextUnorderedListItem">In this trial, Lumason and Perflutren are the contrast agents.</li> <li class="seamTextUnorderedListItem">The scan will take 1-1.5 hours.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06171607' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-biopsy' target='_blank'>Breastcancer.org: Breast Biopsies</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/perflutren-lipid-microsphere-intravenous-route/side-effects/drg-20067608?p=1' target='_blank'>Mayo Clinic: Perflutren Ultrasound Contrast Agent</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/drugs-supplements/sulfur-hexafluoride-lipid-type-a-microspheres-injection-route-intravenous-route/side-effects/drg-20405988?p=1' target='_blank'>Mayo Clinic: Lumason Ultrasound Contrast Agent</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 4 visits

PHASE: NA

NCT ID: NCT05704062

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy Scientific Title

Purpose

To study if MRI scans can earlier and more accurately predict and evaluate response to neoadjuvant (before surgery) chemotherapy.

Who is this for?

People with stage I, stage II, or stage III breast cancer who are planning to receive neoadjuvant (before surgery) chemotherapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans, 4 times over the course of chemotherapy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Neoadjuvant therapy is when you receive treatment, like chemotherapy, before surgery. Doctors use it to shrink tumors and to see how your cancer responds to the given therapies. </li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan is a type of scan that uses a very strong magnet and no radiation or x-ray energy to take very detailed pictures of parts of the body.</li> <li class="seamTextUnorderedListItem">MRI scans are often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment to measure the tumor size changes in response to treatment and plan for surgery.</li> <li class="seamTextUnorderedListItem">MRI scans are used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment.</li> <li class="seamTextUnorderedListItem">You will receive 4 MRI scans: before treatment, after the first treatment cycle, midway through treatment, and at the end of treatment.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05704062' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 3 visits within 6 weeks

PHASE: II

NCT ID: NCT03270059

Gadolinium and Ferumoxytol with MRI Scans for Brain Metastasis

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS Scientific Title

Purpose

To use ferumoxytol and gadolinium to improve the ability of MRI scans to image, diagnose, and study brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Gadolinium, by IV</li> <li class="seamTextUnorderedListItem">Ferumoxytol, by IV</li> <li class="seamTextUnorderedListItem">MRI scans</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Ferumoxytol and gadolinium can increase the visibility of body structures in imaging such as MRI scans.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03270059' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://mriquestions.com/ferumoxytol.html' target='_blank'>MRI Questions: Ferumoxytol</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-gadolinium-based-contrast-agents' target='_blank'>Food and Drug Administration: Gadolinium</a> </li></ul>

NEAREST SITE: 533 miles
OHSU Knight Cancer Institute
Portland,OR

VISITS: 2 visits within 1 week, then 2 visits within 2 months

PHASE: II

NCT ID: NCT03649880

FMISO PET/CT and PET/MRI Scans for Brain Metastasis

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors Scientific Title

Purpose

To study how well FMISO works with imaging techniques to detect tumor behavior and predict cancer progression.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">FMISO tracer, by IV</li> <li class="seamTextUnorderedListItem">PET/CT scan or PET/MRI scan, 2 scans within 1 week, then 2 scans within 2 months</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called ¹⁸F-fluoromisonidazole (FMISO).</li> <li class="seamTextUnorderedListItem">FMISO with PET/CT and PET/MRI imaging techniques produce images of the brain that may help investigators see how much oxygen is getting in the brain tumors.</li> <li class="seamTextUnorderedListItem">The imaging techniques will study if brain tumor cells have low oxygen levels, called tumor hypoxia, which helps cancer cells grow.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03649880' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern/Simmons Cancer Center-Dallas
Dallas,TX

VISITS: 4 visits

PHASE: II-III

NCT ID: NCT04715958

Ultrasound Scans to Predict Response to Chemotherapy Before Surgery for Stage I-III Breast Cancer

Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation Scientific Title

Purpose

To study if ultrasound scans with perflutren (Definity®), an experimental contrast dye, can predict response to chemotherapy.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who are planning to receive chemotherapy before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound scan with perflutren (Definity®), by IV, 3 times</li> <li class="seamTextUnorderedListItem">Utrasound scan, 4 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Perflutren (Definity®) is an experimental contrast dye used to create better images during ultrasounds. </li> <li class="seamTextUnorderedListItem">The ability of cancer treatment to work is affected by the pressure in the cancer.</li> <li class="seamTextUnorderedListItem">Ultrasound scans use sound waves to produce images of structures within your body.</li> <li class="seamTextUnorderedListItem">The ultrasound scan in this trial, contrast-enhanced ultrasound, may be able to detect pressures in cancer and therefore predict response to chemotherapy before surgery (neoadjuvant).</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04715958' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 1509 miles
UT Southwestern Medical Center
Dallas,TX

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT03067467

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) Scientific Title

Purpose

To look at how the metabolism of brain metastases differs from normal tissue.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) and who have not received prior chemotherapy or radiation for these metastases. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will undergo the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRSI (a type of MRI), with contrast, by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRSI (Magnetic Resonance Spectroscopic Imaging) is a technique used to visualize tumor metabolism in real-time.</li> <li class="seamTextUnorderedListItem">Learning how the metabolism of brain metastases differs from normal tissue may lead to the development of new targeted therapies.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03067467' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 1615 miles
Mayo Clinic in Rochester
Rochester,MN

VISITS: 1-2 visits within 6 months

PHASE: NA

NCT ID: NCT06058650

Molecular Breast Imaging to Guide Biopsy

Pilot Clinical Study to Evaluate Molecular Breast Imaging- Guidance for Sampling of Breast Abnormalities Scientific Title

Purpose

To study how well molecular breast imaging (MBI) helps guide the collection of cells during a breast biopsy.

Who is this for?

Women who previously received breast imaging with mammography, ultrasound, MRI, or molecular breast imaging (MBI). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 2 groups: Group 1: Biopsy Not Recommended or Previous Imaging/Biopsy Showed Benign (Normal) Results <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI), 1 time</li> </ul> Group 2: Biopsy Recommended <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI), 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast biopsy</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Collection of abnormal cells during a biopsy is often guided by either ultrasound or mammography in order to ensure that a sample of the correct part of the breast is taken.</li> <li class="seamTextUnorderedListItem">Sometimes abnormal tissue cannot be seen on ultrasound or mammography, and therefore, a biopsy guided with ultrasound or mammography may not always be accurate.</li> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) is a method for detecting abnormal cells on a scan that uses injection of a radioactive tracer. Breast cancer cells take up this tracer more than normal cells, and this allows doctors to see the cancer cells on a scan.</li> <li class="seamTextUnorderedListItem">Technetium Tc-99m sestamibi is the tracer used in this study.</li> <li class="seamTextUnorderedListItem">MBI may improve the detection of some breast tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06058650' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/molecular-breast-imaging' target='_blank'>Breastcancer.org: Molecular Breast Imaging</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT05342454

MRI Scans to Improve Brain Surgery for People with Brain Metastases

A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain Scientific Title

Purpose

To use MRI scans and CVR mapping to develop a new software to improve brain surgery.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning on receiving a fMRI before brain surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">fMRI scans</li> <li class="seamTextUnorderedListItem">CVR mapping</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A functional MRI (fMRI) scan measures changes in blood flow that happen during mental activity.</li> <li class="seamTextUnorderedListItem">Cerebrovascular reactivity (CVR) mapping measures changes in blood flow to your brain.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05342454' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologyinfo.org/en/info/fmribrain' target='_blank'>RadiologyInfo.org: Functional MRI (fMRI)</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 2 visits within 3 months

PHASE: NA

NCT ID: NCT05056844

Mammogram with Contrast to Detect Breast Cancer in Women with Abnormal Nipple Discharge

Contrast Enhanced Spectral Mammography (CESM) for the Evaluation of Pathologic Nipple Discharge: A Pilot Study Scientific Title

Purpose

To learn if contrast enhanced spectral mammography (CESM) is better than standard mammography for determining the cause of nipple discharge and detecting breast cancer.

Who is this for?

Women with abnormal fluid coming from the nipple (discharge) who receive care at MD Anderson Cancer Center in Houston, TX. You must not have been diagnosed with breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast enhanced spectral mammography (CESM)</li> <li class="seamTextUnorderedListItem">Digital tomosynthesis mammography</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A mammogram is a breast cancer screening procedure involving taking an x-ray picture of the breast.</li> <li class="seamTextUnorderedListItem">Mammograms can identify areas of concern, but many areas (lesions) turn out to not be cancer.</li> <li class="seamTextUnorderedListItem">Contrast enhanced spectral mammography (CESM) is similar to standard mammography, but it includes an intravenous (by vein) injection of contrast, which makes tissue and blood vessels more visible in scans.</li> <li class="seamTextUnorderedListItem">CESM may increase the chance of finding breast cancers and decrease unnecessary biopsies.</li> <li class="seamTextUnorderedListItem">A breast tomosynthesis (DBT) mammogram takes multiple pictures of your breast from more angles than a standard mammogram.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05056844' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/what-is-a-contrast-enhanced-mammogram.h00-159701490.html' target='_blank'>MD Anderson Cancer Center: What is a Contrast-Enhanced Mammogram?</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/15939-digital-breast-tomosynthesis-and-breast-cancer-screening' target='_blank'>Cleveland Clinic: Breast Tomosynthesis</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 1 to 2 visits

PHASE: I

NCT ID: NCT03604315

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT Scientific Title

Purpose

To study the safety and effectiveness of using a PET/CT scan with the experimental tracer F-18.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer or DCIS. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">F-18 tracer, by IV, then a PET/CT scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this imaging trial is called fluorine F 18 fluorthanatrace (F-18)--it binds to PARP expressing tumor cells (PARP is a protein over expressed in certain cancers). </li> <li class="seamTextUnorderedListItem">You do not need to have an inherited BRCA1/2 mutation to enroll in this trial but researchers are studying whether F-18 works better in inherited BRCA1/2+ cancers. </li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of solid tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03604315' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/10123-pet-scan' target='_blank'>Cleveland Clinic: PET Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>NCI Drug Dictionary: Fluorine F 18 Fluorthanatrace</a> </li></ul>

NEAREST SITE: 1643 miles
M D Anderson Cancer Center
Houston,TX

VISITS: 2 visits within 2 weeks

PHASE: NA

NCT ID: NCT05042687

Molecular Breast Imaging Scan for Women at High Risk of Breast Cancer

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer Scientific Title

Purpose

To compare the accuracy of molecular breast imaging (MBI) to breast magnetic resonance imaging (MRI) to detect breast cancer.

Who is this for?

Women at high risk for breast cancer who are planning to receive a breast MRI. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Breast MRI scan, 1 time</li> </ul> followed 2 weeks later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) scan with technetium99m (Tc99m), by IV, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Molecular breast imaging (MBI) is a method for detecting abnormal cells on a scan that uses injection of a radioactive tracer. Breast cancer cells take up this tracer more than normal cells, and this allows doctors to see the cancer cells on a scan.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Technetium99m (Tc99m) is the tracer used in this study.</li> <li class="seamTextUnorderedListItem">If you do not speak English, an interpreter will help you translate.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05042687' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/molecular-breast-imaging/about/pac-20394710' target='_blank'>Mayo Clinic: Molecular Breast Imaging</a> </li></ul>

NEAREST SITE: 1678 miles
UW Carbone Cancer Center
Madison,WI

VISITS: 2 visits within 1 month

PHASE: II

NCT ID: NCT06067503

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- Lobular Breast Cancer

Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer Scientific Title

Purpose

To identify possible biomarkers of response to hormone therapy for advanced lobular breast cancer.

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) hormone receptor positive (ER+ or ER low and/or PR+ or PR low), HER2 negative (HER2-) lobular breast cancer (LBC) who are planning to receive hormone therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scans with 18F-FFNP, by IV, 2 times, at baseline and at 1 month</li> <li class="seamTextUnorderedListItem">Blood tests, 2 times, at baseline and at 1 month</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biomarkers are genes, molecules, or other features present in a person, including in a person’s tumor, that tell doctors something about a person’s health condition.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">The tracer used in this study is 18F-FFNP.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy. MRI scans study the blood vessels in the tumor. PET/CT scans study if the tumor cells are growing.</li> <li class="seamTextUnorderedListItem">The blood samples will be used to conduct DNA and circulating tumor cell (CTC) testing.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are cancer cells from a tumor that circulate in the bloodstream.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06067503' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment' target='_blank'>National Cancer Institute: Biomarker Testing</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/pet-scans' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/ct-scan' target='_blank'>Breastcancer.org: CT Scans</a> </li></ul>

NEAREST SITE: 1761 miles
University of Wisconsin School of Medicine and Public Health
Madison,WI

VISITS: Number of visits unavailable

PHASE: II

NCT ID: NCT04573231

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer With 18F-DCFPyL PSMA-based PET/CT Scientific Title

Purpose

To evaluate prostate specific membrane antigen (PSMA) expression in breast cancer to determine people most likely to benefit from anti-androgen therapies.

Who is this for?

People with metastatic (stage IV) HER2 negative (HER2-), androgen receptor positive (AR+) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan with 18F-DCFPyL</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTC) test</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Prostate specific membrane antigen (PSMA) expression may correlate with resistance to anti-androgen therapies, which has been documented in prostate cancer.</li> <li class="seamTextUnorderedListItem">Evaluating PSMA expression may be used to select people most likely to benefit from anti-androgen therapies, such as bicalutamide (Casodex®), in future clinical trials.</li> <li class="seamTextUnorderedListItem">18F-DCFPyL is a tracer that is used to visualize PSMA expression during imaging scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">Circulating tumor cells (CTCs) are breast cancer cells that leave the tumor and move through the bloodstream.</li> <li class="seamTextUnorderedListItem">Targets or mutations: PSMA, AR</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04573231' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/psma-new-target-prostate-cancer-treatment' target='_blank'>Memorial Sloan Kettering Cancer Center: PSMA</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/from-the-experts/ctc/#:~:text=A%20circulating%20tumor%20cell%20(CTC,test%20for%20metastatic%20breast%20cancer.' target='_blank'>Metastatic Trial Talk: Circulating Tumor Cell Testing</a> </li></ul>

NEAREST SITE: 1832 miles
Medical College of Wisconsin
Milwaukee,WI

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT06383026

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Understanding Breast Cancer Risk and Screening in Transgender and Gender-Diverse Persons Through a Pilot Breast Cancer Screening Program Scientific Title

Purpose

To study the breast cancer screening perceptions and experiences of transgender and gender-diverse people and understand factors that make breast cancer screening more difficult.

Who is this for?

Transgender and gender-diverse people at least 30 years old who have received gender-affirming hormone therapy. You must not have a history of breast cancer or a known genetic mutation that increases your risk for breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Mammogram</li> <li class="seamTextUnorderedListItem">Whole breast ultrasound</li> <li class="seamTextUnorderedListItem">Surveys</li> <li class="seamTextUnorderedListItem">Interviews</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Transgender and gender-diverse people may experience barriers and non-equitable treatment by healthcare professionals that make receiving breast cancer screening more difficult.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06383026' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2013 miles
The University of Alabama at Birmingham
Birmingham,AL

VISITS: 3-4 visits

PHASE: I

NCT ID: NCT04332588

PET/MRI Scans to Monitor Response to Trastuzumab (Herceptin®) for Women with Stage II-III HER2+ Breast Cancer

Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI Scientific Title

Purpose

To determine if PET/MRI scans with 18FFMISO can help monitor and predict the effect of trastuzumab (Herceptin®).

Who is this for?

Women with newly diagnosed stage II or stage III HER2 positive (HER2+) breast cancer who have not yet received treatment and are planning to receive trastuzumab (Herceptin®) before surgery (neoadjuvant). Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/MRI scan with 18FFMISO and gadoteridol (Prohance®), by IV, 2-3 times</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18FFMISO is an experimental imaging tracer for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">Gadoteridol (Prohance®) is a standard of care imaging contrast agent for use in PET/MRI scans.</li> <li class="seamTextUnorderedListItem">The results of this study will not change your treatment plan, but it may help doctors and researchers better understand how best to treat people with breast cancer in the future.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04332588' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2168 miles
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland,OH

VISITS: 1 visit

PHASE: NA

NCT ID: NCT02956291

Magnetic Resonance Fingerprinting for Brain Metastases

Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors Scientific Title

Purpose

To study the safety and effects of magnetic resonance fingerprinting

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastases) Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Magnetic resonance fingerprinting is a type of MRI.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02956291' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2193 miles
Cleveland Clinic, Case Comprehensive Cancer Center
Cleveland,OH

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04348123

Providing Screening Mammograms to Women Experiencing Homelessness in Cleveland, Ohio

A Proposed Community-Based Interventional Program That Educates, Identifies And Overcomes Barriers to Complete Screening Mammography Among Homeless Women Scientific Title

Purpose

To provide mammograms to increase screening rates and decrease late-stage breast cancer diagnoses in women who are experiencing homelessness.

Who is this for?

Women who have not had a mammogram in the last year and are residents at a homeless shelter or transitioning housing facility near Cleveland, Ohio. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will complete the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Attend education session about breast health and mammograms</li> <li class="seamTextUnorderedListItem">Receive mammogram (optional)</li> <li class="seamTextUnorderedListItem">Complete survey</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The education sessions will explain breast health, mammography, and screening options and address common barriers.</li> <li class="seamTextUnorderedListItem">Mammograms use X-rays to screen for breast cancer.</li> <li class="seamTextUnorderedListItem">In this trial, the mammograms are optional and will be provided at no cost (free).</li> <li class="seamTextUnorderedListItem">Spanish speaking staff will be available for the educational sessions.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04348123' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/mammograms' target='_blank'>Breastcancer.org: Mammograms</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT06456411

Brain Scan and Virtual Reality to Decrease Pain for People with Stage 0-IV Breast Cancer

Real-Time Evaluation of Severity of Perceived Pain in Patients With Cancer by Using Functional Near-Infrared Spectroscopy (fNIRS), and Investigation of Pain Relief Utilizing Virtual Reality Technologies Scientific Title

Purpose

To study whether a virtual reality relaxation program can decrease pain and if this can be seen in the brain with a functional near-infrared spectroscopy scan.

Who is this for?

People with stage 0 (DCIS), stage I, stage II, stage III, or stage IV (metastatic) breast cancer who are experiencing pain from treatment, and people who do not have breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Virtual Reality and Scan <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Functional near-infrared spectroscopy scan, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Virtual reality, 1 time, at least 15 minutes</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> Group 2: Scan Only <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Functional near-infrared spectroscopy scan, 1 time</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Functional near-infrared spectroscopy is a non-invasive type of imaging scan that can show pictures of the brain and brain activity.</li> <li class="seamTextUnorderedListItem">Virtual reality (VR) is a computer-generated experience that simulates the 3D environment.</li> <li class="seamTextUnorderedListItem">Virtual reality relaxation programs may help relieve pain in people with cancer who are receiving treatment. Relief of pain may be seen on a functional near-infrared spectroscopy scan.</li> <li class="seamTextUnorderedListItem">Results from people who do not have breast cancer will be compared to results from people with breast cancer.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06456411' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.techtarget.com/whatis/definition/virtual-reality' target='_blank'>Tech Target: What is Virtual Reality?</a> </li></ul>

NEAREST SITE: 2299 miles
Roswell Park Cancer Institute
Buffalo,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03897270

Photoacoustic Imaging (A Scan That Uses Waves and Light) to Study Breast Tissue and Tumors in Women

Photoacoustic Imaging of Human Breast Scientific Title

Purpose

To study breast tissue and tumors by using photoaccoustic imaging (a type of scan that uses sound and light to study tissue).

Who is this for?

Women diagnosed with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have received or are planning to receive a breast MRI. You may also enroll if you have not been diagnosed with breast cancer but are scheduled to receive an MRI to look at a suspicious mass (lump) in your breast. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Photoacoustic imaging of the breast, for about 30 minutes, once</li> </ul> You may choose to repeat this process up to 10 times (on separate days)
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Research shows that mammograms are more difficult to read in women with dense breasts.</li> <li class="seamTextUnorderedListItem">Photoacoustic imaging is a type of scan that uses sound and light to study breast tissue.</li> <li class="seamTextUnorderedListItem">Researchers are studying whether photoacoustic imaging makes it easier to see tumors in women with dense breasts.</li> <li class="seamTextUnorderedListItem">They are also studying if they can learn anything new about breast tissue and tumors with this experimental imaging technique.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03897270' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://en.wikipedia.org/wiki/Photoacoustic_imaging' target='_blank'>Wikipedia: Photoacoustic Imaging</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/types/breast/breast-changes/dense-breasts' target='_blank'>NCI Breast Cancer: Dense Breasts</a> </li><li class='seamTextUnorderedListItem'><a href='https://dmm.biologists.org/content/12/7/dmm039636' target='_blank'>Journal Article: Photoacoustic Imaging as a Tool to Probe the Tumour Microenvironment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005545/' target='_blank'>Journal Article: Photoacoustic Imaging of Breast Cancer</a> </li></ul>

NEAREST SITE: 2325 miles
Hawaii Radiology Associates, LTD (East Hawaii Women's Imaging Center)
Hilo,HI

VISITS: 1 visit

PHASE: NA

NCT ID: NCT05369546

Improving Digital Breast Tomosynthesis to Better Identify Breast Lesions That Require a Biopsy

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis Scientific Title

Purpose

To improve the use of digital breast tomosynthesis (DBT) to better identify suspicious breast lesions that need to be biopsied.

Who is this for?

Women with a suspicious area on a mammogram who have not yet had a biopsy. You must not have a history of breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT), 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most breast biopsies (71%) in the US do not result in a diagnosis of cancer. This means that many biopsies are unnecessary.</li> <li class="seamTextUnorderedListItem">A new way to use digital breast tomosynthesis (DBT) may reduce unnecessary biopsies.</li> <li class="seamTextUnorderedListItem">Digital breast tomosynthesis (DBT) is an advanced mammogram that takes multiple pictures of your breast from more angles than a standard mammogram.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05369546' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2406 miles
University of North Carolina at Chapel Hill, Department of Radiation Oncology
Chapel Hill,NC

VISITS: Number of visits unavailable

PHASE: NA

NCT ID: NCT04073966

Studying Brain Function Changes During Radiation in People with Brain Metastases

Magnetic Resonance Imaging Biomarkers for Radiation-Induced Neurocognitive Decline Following Stereotactic Radiosurgery of Newly Diagnosed Brain Metastases: An Observational Pilot Study Scientific Title

Purpose

To study why radiation causes brain function changes to help doctors predict and prevent brain function changes.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are receiving stereotactic radiosurgery (SRS). You must not have received surgery to the lesion receiving SRS or any radiation to the brain or head. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI scans</li> <li class="seamTextUnorderedListItem">Neurocognitive function tests</li> </ul> Please contact research site for trial schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery (SRS) is a type of radiation therapy that delivers a high dose of radiation only to the areas of cancer in the brain and avoids the surrounding normal brain tissue.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04073966' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2406 miles
University of North Carolina at Chapel Hill
Chapel Hill,NC

VISITS: 1 visit in 1 day

PHASE: I

NCT ID: NCT05754749

Contrast-Enhanced Digital Breast Tomosynthesis for People with Breast Cancer

Comparison of Contrast Enhanced Digital Breast Tomosynthesis and Magnetic Resonance Imaging in Patients With Known Breast Lesions Scientific Title

Purpose

To study the ability of contrast-enhanced digital breast tomosynthesis (CE-DBT) to detect breast tumors compared to contrast-enhanced dynamic magnetic resonance imaging (CE-MRI).

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have received or are planning to receive a breast MRI at a University of North Carolina (UNC) hospital. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Contrast-enhanced digital breast tomosynthesis (CE-DBT)</li> <li class="seamTextUnorderedListItem">Iohexol, by IV</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A digital breast tomosynthesis (DBT) is an advanced mammogram that takes multiple pictures of your breast from more angles than a standard mammogram.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Contrast-enhanced digital breast tomosynthesis (CE-DBT) includes injections of iohexol contrast dye to detect and visualize cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05754749' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/15939-digital-breast-tomosynthesis-and-breast-cancer-screening' target='_blank'>Cleveland Clinic: Digital Breast Tomosynthesis</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/diagnostics/4876-magnetic-resonance-imaging-mri' target='_blank'>Cleveland Clinic: Magnetic Resonance Imaging</a> </li></ul>

NEAREST SITE: 2477 miles
Carolina Breast Imaging Specialists
Greenville,NC

VISITS: 3 visits within 2 years

PHASE: NA

NCT ID: NCT05625659

Imaging to Improve Breast Cancer Screening in Women With Dense Breasts

Comparison of Breast Cancer Screening With Dual-Energy Contrast-Enhanced Spectral Mammography to Digital Breast Tomosynthesis in Women With Dense Breasts (Contrast Mammography Imaging Screening Trial Scientific Title

Purpose

To study if dual-energy contrast-enhanced spectral mammography (CESM) can improve breast cancer screening in women with dense breasts.

Who is this for?

Women 45-74 years old with dense breasts. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Standard mammogram, 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Contrast-enhanced spectral mammography (CESM), 2 times within 1 year</li> <li class="seamTextUnorderedListItem">Imaging contrast, by IV, 2 times within 1 year</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Email, text, or phone call</li> <li class="seamTextUnorderedListItem">Return to standard mammography for breast cancer screening</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dual-energy contrast-enhanced spectral mammography (CESM) uses contrast to improve detection of breast cancer compared to standard mammograms.</li> <li class="seamTextUnorderedListItem">Some cancers, such as those present in dense breast tissue, may be visible on CESM but not on a standard mammogram.</li> <li class="seamTextUnorderedListItem">Breast cancer is harder to see on a mammogram of dense breasts.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05625659' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://densebreast-info.org/screening-technologies/contrast-enhanced-mammography/#:~:text=CEM%20can%20be%20used%20to,or%20abnormalities%20seen%20on%20mammograms.' target='_blank'>Dense Breast Info.org: Contrast-Enhanced Mammograms</a> </li><li class='seamTextUnorderedListItem'><a href='https://densebreast-info.org/for-patients/5-facts-you-should-know/' target='_blank'>Dense Breast Info.org: What to Know About Dense Breasts</a> </li></ul>

NEAREST SITE: 2517 miles
University of Pennsylvania
Philadelphia,PA

VISITS: 1 to 4 visits

PHASE: I

NCT ID: NCT03863457

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Pilot Study Evaluating the Uptake of [18F] F-GLN by PET/CT in Breast Cancer Scientific Title

Purpose

To study the safety and effectiveness of an experimental PET/CT scan tracer (a radioactive substance that looks for and attaches to cancer cells).

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who have at least one tumor 1.5 cm or larger. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following 1 to 4 times: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">(18F)F-GLN tracer, by IV, then a PET/CT scan</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">Cancer cells use a protein called glutamine to grow--they use more of it than healthy cells. </li> <li class="seamTextUnorderedListItem">This imaging trial will use a tracer called (18F) F-GLN--it shows which cells in your body are using a lot of glutamine. </li> <li class="seamTextUnorderedListItem">A (18F) F-GLN PET/CT scan may work better than standard of care PET/CT scans in finding cancer tumors.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03863457' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/testing/types/pet' target='_blank'>Breastcancer.org: PET Scans</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mskcc.org/news/beyond-sugar-what-cancer-cells-need-grow' target='_blank'>Memorial Sloan Kettering Cancer Center: Beyond Sugar, What Cancer Cells Need to Grow</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373500/' target='_blank'>Journal Article: Metabolic Imaging of Glutamine in Cancer</a> </li></ul>

NEAREST SITE: 2517 miles
UPENN
Philadelphia,PA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT04854304

Fast Breast MRI to Screen for Breast Cancer in Black Women with High Breast Density

Supplemental Screening for Breast Cancer With Abbreviated Breast MR for Black Women With Increased Breast Density Scientific Title

Purpose

To screen for breast cancer in black women with high breast density using Fast Breast MRI.

Who is this for?

Black women without breast cancer that have high breast density indicated by scores C (heterogeneously dense) and D (extremely dense) on the Breast Imaging Reporting and Data System (BI-RADS) scale. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fast Breast MRI, 1 session</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Fast Breast MRI takes about 10 minutes to perform.</li> <li class="seamTextUnorderedListItem">Dense breasts make it harder for doctors to see breast cancers on mammograms.</li> <li class="seamTextUnorderedListItem">Women with dense breasts have a higher risk of developing breast cancer compared to women who don’t have dense breasts. </li> <li class="seamTextUnorderedListItem">For people with dense breasts, screening with Fast Breast MRI is sometimes recommended to detect breast cancer that might not be visible on a mammogram.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04854304' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/fast-mri-better-than-3d-mammo-for-dense-breasts#:~:text=Traditional%20breast%20MRI%20uses%20magnets,breast%20MRI%20is%20not%20perfect.' target='_blank'>Breastcancer.org: Fast Breast MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/risk/factors/dense_breasts' target='_blank'>Breastcancer.org: Dense Breasts</a> </li></ul>

NEAREST SITE: 2517 miles
University of Pennsylvania
Philadelphia,PA

VISITS: 1-2 visits

PHASE: NA

NCT ID: NCT03846167

PET/CT Scans with 18F-FTT to Study PARP-1 Activity in Breast Cancer

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) Scientific Title

Purpose

To study if PET/CT scans with 18F-FTT can detect tumors that have PARP-1 activity.

Who is this for?

People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer receiving treatment at the University of Pennsylvania. If you have stage I, stage II, or some stage III breast cancer, you must have not yet received surgery. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FTT, by injection </li> <li class="seamTextUnorderedListItem">PET/CT scan, 1-2 scans</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan, 1-2 scans (optional after beginning first or next treatment)</li> </ul> Please contact research site for treatment schedule
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-FTT is an experimental imaging agent used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into your body to see where there is active breast cancer.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">PARP, or poly (ADP-ribose) polymerase, is an enzyme that helps cancer cells grow by repairing their DNA.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03846167' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fluorine-f-18-fluorthanatrace' target='_blank'>National Cancer Institute: 18F-FTT</a> </li></ul>

NEAREST SITE: 2519 miles
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia,PA

VISITS: 1 visit

PHASE: NA

NCT ID: NCT05408260

2 Types of Ultrasound to Detect Recurrence After Mastectomy with Reconstruction

Feasibility of Automated Breast Ultrasound (ABUS) Versus Handheld Ultrasound (HHUS) for Breast Cancer Surveillance in Women With Nipple Sparing or Skin Sparing Mastectomy With Reconstruction Scientific Title

Purpose

To study if 2 types of ultrasound can detect breast cancer recurrence after mastectomy with reconstruction.

Who is this for?

Women with stage I, stage II, or stage III breast cancer who have completed treatment and have no history of recurrence. You must have received a nipple-sparing mastectomy or skin-sparing mastectomy with reconstruction on one breast that was performed at Thomas Jefferson University Hospital within the last 5 years. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Handheld ultrasound (HHUS), 1 time</li> <li class="seamTextUnorderedListItem">Automated breast ultrasound (ABUS), 1 time</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Ultrasound uses high-frequency sound waves to create pictures of internal organs and tissues.</li> <li class="seamTextUnorderedListItem">Automated breast ultrasound (ABUS) has been found to be equal to handheld ultrasound (HHUS) for whole breast screening, and this trial will study their use for breast cancer screening of people who have undergone breast reconstruction.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05408260' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/breast-ultrasound' target='_blank'>Johns Hopkins: Breast Ultrasound</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/surgery/breast-reconstruction/screening-after-reconstruction' target='_blank'>Breastcancer.org: Screening After Mastectomy</a> </li></ul>

NEAREST SITE: 2539 miles
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge,NJ

VISITS: 2-4 visits

PHASE: I

NCT ID: NCT04692831

Imaging Agent for PET/CT Scans to Identify Metastatic HER2+ Breast Cancer

Imaging of HER2-positive Cancer With Site-Specifically Labeled 89Zr-ss-Pertuzumab Scientific Title

Purpose

To study the safety and effects (good and bad) of 89Zr-ss-pertuzumab, an experimental tracer used for PET/CT scans.

Who is this for?

People with stage IV (metastatic) HER2 positive (HER2+) breast cancer. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">89Zr-ss-pertuzumab, by IV, 1 time</li> </ul> followed by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan, 1-3 times within 1 week</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">89Zr-ss-pertuzumab is an experimental tracer, also called imaging agent, for PET/CT scans.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04692831' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2021-00534&r=1' target='_blank'>National Cancer Institute: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/tests/pet-ct-scan' target='_blank'>Cancer Research UK: PET/CT Scan</a> </li></ul>

NEAREST SITE: 2567 miles
Memorial Sloan Kettering Cancer Center
New York,NY

VISITS: 3 visits within 1 year

PHASE: NA

NCT ID: NCT05130840

MRI Scans and Lumbar Punctures to Detect Brain Metastasis in People with HER2+ Breast Cancer

Feasibility of Multi-modality Central Nervous System Evaluation in HER2+ Breast Cancer Patients Scientific Title

Purpose

To study if MRI brain scans and cerebrospinal fluid tests can detect brain metastasis early.

Who is this for?

People with stage II, stage III, or stage IV (metastatic) HER2 positive (HER2+) breast cancer. If you have stage IV (metastatic) breast cancer, you must have received at least 1 line of anti-HER2 targeted therapy. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">MRI brain scan, 3 times within 1 year</li> <li class="seamTextUnorderedListItem">Lumbar puncture, 3 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">A lumbar puncture, also known as a spinal tap, is a procedure to remove a sample of cerebrospinal fluid (CSF). The presence of cancer in the brain may be detected in the CSF.</li> <li class="seamTextUnorderedListItem">Cerebrospinal fluid (CSF) is the fluid or liquid surrounding your brain and spinal cord.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05130840' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/lumbar-puncture/about/pac-20394631' target='_blank'>Mayo Clinic: Lumbar Puncture (Spinal Tap)</a> </li></ul>

NEAREST SITE: 2569 miles
Mount Sinai
New York,NY

VISITS: Coincides with routine care

PHASE: NA

NCT ID: NCT04983875

Sharing Breast Arterial Calcification Results After Mammograms

Enhancing the Public Health Benefits of Mammography Screening by Informing Women of Both Breast Cancer and Breast Arterial Calcification Results: A Randomized Trial to Promote Cardiovascular Health Scientific Title

Purpose

To study the potential benefits of adding breast arterial calcification (BAC) results to the standard results letter women receive after mammography.

Who is this for?

Women at least 40 years old who are planning to receive a mammogram at a Mount Sinai breast radiology clinic. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be randomly assigned to 1 of 2 groups: Group 1: Experimental <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive a letter after your mammogram with your breast arterial calcification (BAC) status</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 6 months</li> </ul> Group 2: Standard of Care <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive standard of care letter after your mammogram without your breast arterial calcification (BAC) status</li> <li class="seamTextUnorderedListItem">Questionnaires, 2 times within 6 months</li> </ul> followed 6 months later by: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Receive information about BAC status</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In addition to detecting potential breast cancer, mammograms can also detect the presence of calcifications within the breast arteries (blood vessels). </li> <li class="seamTextUnorderedListItem">Those calcifications, called BAC, can be associated with a disease of the heart and blood vessels called coronary artery disease.</li> <li class="seamTextUnorderedListItem">Currently, women are not routinely told whether or not they have BAC.</li> <li class="seamTextUnorderedListItem">Previous research has suggested that patients would like to be informed about their BAC status.</li> <li class="seamTextUnorderedListItem">This trial is also available in Spanish.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04983875' target='_blank'>ClinicalTrials.gov</a> </li></ul>

NEAREST SITE: 2574 miles
Montefiore Medical Center
Bronx,NY

VISITS: 1 visit

PHASE: NA

NCT ID: NCT03694756

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

TMEM-MRI: A Pilot Feasibility Study of Magnetic Resonance Imaging for Imaging of TMEM (Tumor Microenvironment of Metastasis) in Patients With Operable Breast Cancer Scientific Title

Purpose

To study the ability of TMEM-MRI, an experimental type of MRI scan, to detect breast cancer cells.

Who is this for?

People with a breast mass that is suspected to be breast cancer, or people with stage I, stage II, or some stage III breast cancer who have not yet received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">TMEM-MRI scan, 1 time</li> <li class="seamTextUnorderedListItem">Contrast agent, by IV, 1 time</li> <li class="seamTextUnorderedListItem">Biopsy (if you have not yet received one)</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">Tumor Microenvironment of Metastasis - Magnetic Resonance Imaging (TMEM-MRI) scans are an experimental type of MRI scan that can detect tumor areas that are more likely to travel to other sites in the body.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may be useful to identify tumors with a higher chance of coming back (recurrence) after treatment.</li> <li class="seamTextUnorderedListItem">TMEM-MRI scans may also be useful for studying the response to neoadjuvant (before surgery) treatment such as chemotherapy and hormone therapy.</li> <li class="seamTextUnorderedListItem">A contrast agent, also called a tracer, is a radioactive substance that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03694756' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/screening-testing/breast-mri' target='_blank'>Breastcancer.org: Breast MRI</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute
Miami,FL

VISITS: 3 visits

PHASE: I

NCT ID: NCT04689048

18F-Fluciclovine and PET/CT Scans for Brain Metastasis

Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery Scientific Title

Purpose

To study the ability of 18F-fluciclovine and PET/CT scans to detect responses to radiation therapy and changes in brain metastasis.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive treatment with stereotactic radiosurgery. You must have at least 1 brain tumor that has not received treatment. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine (Axumin®), by IV, 3 times</li> <li class="seamTextUnorderedListItem">PET/CT brain scans, 3 scans</li> </ul> Please contact research site for treatment schedule.
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">18F-fluciclovine is an experimental tracer that may be able to detect your response to staged stereotactic radiosurgery.</li> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">The PET/CT scans will be administered before, during, and after treatment with stereotactic radiosurgery.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04689048' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li></ul>

NEAREST SITE: 2587 miles
Miami Cancer Institute at Baptist Health South Florida
Miami,FL

VISITS: 4-5 visits within 1 year

PHASE: II

NCT ID: NCT05554302

PET/CT and MRI Scans After Surgery to Monitor Brain Metastases

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis Scientific Title

Purpose

To study the ability of PET/CT scans with 18F-Fluciclovine to help doctors monitor brain metastases after surgery compared to MRI scans.

Who is this for?

People with metastatic (stage IV) breast cancer that has spread to the brain (brain metastasis) who are planning to receive surgery and radiation. You must not have received whole brain radiation. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will receive the following: <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">PET/CT scan, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine, by IV, 4-5 times within 1 year</li> <li class="seamTextUnorderedListItem">MRI scan, 4 times within 1 year</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A positron emission tomography (PET) scan is an imaging test that uses a radioactive substance called a tracer that can look for and attach to cancer cells.</li> <li class="seamTextUnorderedListItem">A computed tomography (CT) scan produces body pictures created by x-ray energy.</li> <li class="seamTextUnorderedListItem">A magnetic resonance imaging (MRI) scan produces body pictures created by using magnetic energy rather than x-ray energy.</li> <li class="seamTextUnorderedListItem">18F-Fluciclovine is an experimental radioactive substance called a tracer that can look for and attach to cancer cells.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05554302' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://mbcbrainmets.org/' target='_blank'>MBCBrainMets.org</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.healthline.com/health/mri-vs-pet-scan#pet-ct-or-pet-mri' target='_blank'>Healthline: PET/CT Scans vs. MRI Scans</a> </li></ul>

NEAREST SITE: 2693 miles
Brigham and Women's Hospital
Boston,MA

VISITS: 1 visit every 6 months, for 2 years

PHASE: NA

NCT ID: NCT04030507

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Screening Magnetic Resonance Imaging of the Brain in Patients With Metastatic Breast Cancer Managed With First/Second Line Chemotherapy or Inflammatory Breast Cancer Managed With Definitive Intent: A Prospective Study Scientific Title

Purpose

To study if using MRIs to screen for brain metastases (breast cancer that has spread to the brain) is safe and finds brain metastases earlier than the standard of care (no screening).

Who is this for?

People with advanced (some stage III) or metastatic (stage IV) breast cancer who will be starting their first or second chemotherapy for advanced disease. Full eligibility criteria

Contact research site

Share with my doctor

Share with my patient

Contact Research Sites

What's involved?
What's being studied?
How can I learn more?

You will be assigned to 1 of 3 groups depending upon your cancer subtype: Group 1: Triple negative <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 2: Inflammatory <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> Group 3: Hormone positive or HER2 positive People in Group 3 will be randomly assigned to receiving screening or no screening Screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain MRI, every 6 months for 2 years</li> </ul> No screening group <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">No brain MRIs</li></ul>
<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Brain metastases (brain mets) is when breast cancer has spread to the brain. </li> <li class="seamTextUnorderedListItem">The standard of care for metastatic breast cancer does not include ongoing screening for brain metastases.</li> <li class="seamTextUnorderedListItem">This imaging trial will use regularly scheduled MRIs (magnetic resonance imaging) to look for brain mets.</li> <li class="seamTextUnorderedListItem">Researchers believe adding brain metastases screening to the standard of care will help doctors find brain mets earlier--when they are smaller and potentially easier to manage.</li></ul>
<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04030507' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mayoclinic.org/tests-procedures/mri/about/pac-20384768' target='_blank'>Mayo Clinic: Brain MRI</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.radiologybusiness.com/topics/policy/brain-mri-could-id-metastases-breast-cancer-patients-guidelines-dont-recommend-it' target='_blank'>Radiology Business: Brain MRI Could ID Metastases in Breast Cancer Patients</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancertodaymag.org/Pages/Spring2019/Looking-for-Brain-Metastases.aspx' target='_blank'>Cancer Today: Looking for Brain Metastases</a> </li></ul>

Browse Trials

Narrow my choices:

Imaging and Tumor Mark Tests to Monitor Metastatic HR Positive, HER2 Negative Breast Cancer

Contact Research Sites

PET/CT Scans Before Surgery for People with Stage I-IV Breast Cancer

Contact Research Sites

DIRECT: PET/CT Scan to Predict Response to Chemotherapy Before Surgery for Stage II-III HER2 Positive Breast Cancer

Contact Research Sites

Contrast-Enhanced Ultrasound to Identify Breast Masses

Contact Research Sites

MRI Scans to Predict and Evaluate Response to Chemotherapy Before Surgery for People with Stage I-III Breast Cancer

Contact Research Sites

Gadolinium and Ferumoxytol with MRI Scans for Brain Metastasis

Contact Research Sites

FMISO PET/CT and PET/MRI Scans for Brain Metastasis

Contact Research Sites

Ultrasound Scans to Predict Response to Chemotherapy Before Surgery for Stage I-III Breast Cancer

Contact Research Sites

Metabolic Differences Between Brain Metastases and Normal Brain Tissue

Contact Research Sites

Molecular Breast Imaging to Guide Biopsy

Contact Research Sites

MRI Scans to Improve Brain Surgery for People with Brain Metastases

Contact Research Sites

Mammogram with Contrast to Detect Breast Cancer in Women with Abnormal Nipple Discharge

Contact Research Sites

An Experimental PET/CT Scan to Find PARP-Expressing Tumor Cells

Contact Research Sites

Molecular Breast Imaging Scan for Women at High Risk of Breast Cancer

Contact Research Sites

Biomarkers to Detect Resistance to Hormone Therapy for Advanced HR+, HER2- Lobular Breast Cancer

Contact Research Sites

Evaluating PSMA Expression to Determine Response to Anti-Androgen Therapies for Metastatic HER2-, AR+ Breast Cancer

Contact Research Sites

Understanding Breast Cancer Screening Experiences for Transgender and Gender-Diverse People

Contact Research Sites

PET/MRI Scans to Monitor Response to Trastuzumab (Herceptin®) for Women with Stage II-III HER2+ Breast Cancer

Contact Research Sites

Magnetic Resonance Fingerprinting for Brain Metastases

Contact Research Sites

Providing Screening Mammograms to Women Experiencing Homelessness in Cleveland, Ohio

Contact Research Sites

Brain Scan and Virtual Reality to Decrease Pain for People with Stage 0-IV Breast Cancer

Contact Research Sites

Photoacoustic Imaging (A Scan That Uses Waves and Light) to Study Breast Tissue and Tumors in Women

Contact Research Sites

Improving Digital Breast Tomosynthesis to Better Identify Breast Lesions That Require a Biopsy

Contact Research Sites

Studying Brain Function Changes During Radiation in People with Brain Metastases

Contact Research Sites

Contrast-Enhanced Digital Breast Tomosynthesis for People with Breast Cancer

Contact Research Sites

Imaging to Improve Breast Cancer Screening in Women With Dense Breasts

Contact Research Sites

An Experimental Tracer in PET/CT Scans to Find Breast Cancer Tumors

Contact Research Sites

Fast Breast MRI to Screen for Breast Cancer in Black Women with High Breast Density

Contact Research Sites

PET/CT Scans with 18F-FTT to Study PARP-1 Activity in Breast Cancer

Contact Research Sites

2 Types of Ultrasound to Detect Recurrence After Mastectomy with Reconstruction

Contact Research Sites

Imaging Agent for PET/CT Scans to Identify Metastatic HER2+ Breast Cancer

Contact Research Sites

MRI Scans and Lumbar Punctures to Detect Brain Metastasis in People with HER2+ Breast Cancer

Contact Research Sites

Sharing Breast Arterial Calcification Results After Mammograms

Contact Research Sites

Experimental Breast MRI Scan for People with Suspected Breast Cancer or Stage I-III Breast Cancer

Contact Research Sites

18F-Fluciclovine and PET/CT Scans for Brain Metastasis

Contact Research Sites

PET/CT and MRI Scans After Surgery to Monitor Brain Metastases

Contact Research Sites

Using MRIs to Screen for Brain Metastases in Advanced Breast Cancer

Contact Research Sites

Connect

Site Map